Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients

After the landmark approval of T-VEC, oncolytic viruses are finding their way to the clinics. However, response rates have still room for improvement, and unfortunately there are currently no available markers to predict responses for oncolytic immunotherapy. Interleukin 8 (IL-8) production is upreg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Taipale, Kristian, Tähtinen, Siri, Havunen, Riikka, Koski, Anniina, Liikanen, Ilkka, Pakarinen, Päivi, Koivisto-Korander, Riitta, Kankainen, Matti, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814215/
https://ncbi.nlm.nih.gov/pubmed/29464075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23967
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares